Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-08

Clinical Trial Update: A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) [Phase 2]

View source ↗

Summary

The Phase 2 trial of cemdisiran in adults with immunoglobulin A nephropathy (IgAN) has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cemdisiran (cemdisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Status: TERMINATED | Results posted: 2023-12-08